Literature DB >> 29650638

Actinomyces cavernous sinus infection: a case and systematic literature review.

Michal Lubomski1,2, James Dalgliesh3, Kenneth Lee4, Omprakash Damodaran5, Genevieve McKew6,7, Stephen Reddel1,7.   

Abstract

A 63-year-old man presented with a 2-month history of progressive right-sided exophthalmos, painful ophthalmoplegia and fevers. As more features developed, he was diagnosed with giant cell arteritis, then Tolosa-Hunt syndrome, and transiently responded to corticosteroids. A bland cerebrospinal fluid and highly metabolically active brain (18F)-fluoro-D-glucose-positron emission tomography suggested lymphoma. Biopsy of the mass showed sulphur granules with Gram-positive filamentous bacteria with Actinomyces-like colonies. Actinomyces cavernous sinus infections are rare and indolent. They often mimic non-infective causes including other inflammatory and infiltrative conditions, vascular and neoplastic causes, particularly lymphoma. Clinicians should consider infective cavernous sinus syndromes in people with a fluctuating painful ophthalmoplegia that responds poorly to corticosteroids. The term Tolosa-Hunt syndrome is problematic and should be retired or used only with reservation. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  actinomyces; cavernous sinus; infection; ophthalmoplegia; tolosa-hunt syndrome

Mesh:

Year:  2018        PMID: 29650638     DOI: 10.1136/practneurol-2017-001844

Source DB:  PubMed          Journal:  Pract Neurol        ISSN: 1474-7758


  2 in total

Review 1.  Tolosa-Hunt Syndrome: A Review of Diagnostic Criteria and Unresolved Issues.

Authors:  Paromita Dutta; Kamlesh Anand
Journal:  J Curr Ophthalmol       Date:  2021-07-05

2.  A rare case of Mycobacterium Chelonae infection in an immunocompromised adult with cavernous sinus syndrome.

Authors:  Ye Li; Le Zhang; Chunhui Li; Xuelun Zou; Yi Zeng; Zhiping Hu; Bo Xiao; Lili Long
Journal:  CNS Neurosci Ther       Date:  2022-02-15       Impact factor: 5.243

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.